150812-32-1

Basic information

• Product Name: 2-Amino-4-bromo-5-chlorobenzoic acid
• Synonyms: 2- Amino-4-bromo-5-chlorobenzoic acid;Amino-4-bromo-5-chlorobenzoic acid;4-Bromo-5-chloroanthranilic acid
• CAS NO: 150812-32-1
• Molecular Formula: C₇H₅BrClNO₂
• Molecular Weight: 250.48
• EINECS: 424-700-4
• Product Categories: Multisubstituted Benzene;Chemical Amines;Amines;Aromatics
• Mol File: 150812-32-1.mol

Chemical Properties

• Boiling Point: 385.726 °C at 760 mmHg
• Flash Point: 187.081 °C
• Appearance: Tan solid
• Density: 1.892
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.68
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• Solubility: DMSO, Methanol
• PKA: 4.34±0.10(Predicted)
• CAS DataBase Reference: 2-Amino-4-bromo-5-chlorobenzoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Amino-4-bromo-5-chlorobenzoic acid(150812-32-1)
• EPA Substance Registry System: 2-Amino-4-bromo-5-chlorobenzoic acid(150812-32-1)

Safety Data

• Hazardous Substances Data: 150812-32-1(Hazardous Substances Data)

Usage

Chemical Properties

Tan Solid

InChI:InChI=1/C7H5BrClNO2/c8-4-2-6(10)3(7(11)12)1-5(4)9/h1-2H,10H2,(H,11,12)

Upstream product

• 586-76-5 4-Bromobenzoic acid 
• 108-41-8 1-chloro-3-methylbenzene 

Downstream Products

• 1260847-61-7 7-bromo-4, 6-dichloroquinazoline 
• 17518-98-8 7-bromo-6-chloro-3,4-dihydroquinazolin-4-one 
• 17518-98-8 4-hydroxy-6-chloro-7-bromo-quinazoline 
• 17395-31-2 halofuginone hydrobromide 
• 64544-01-0 7-bromo-6-chloro-3-[3-(3-hydroxyl-2-piperidyl)-2-oxopropyl]quinazolin-4(3H)-one 
• 1951439-31-8 7-bromo-6-chloro-1,2,3,4-tetrahydroquinazoline-2,4-dione 

Relevant articles and documents

Method for preparing normal 2-docodone intermediate (I)-(C)-( -4- C)-(C -5-) bromo-(M-chlorobenzoic acid) (by machine translation)

The method sequentially comprises the following steps: a new, synthetic, route and a selective. reduction 2 - reaction are supplied to the preparation method of the anti.coccidiosis intermediate, and: the method sequentially comprises the following, steps

A novel synthesis of the efficient anti-coccidial drug halofuginone hydrobromide

Background: Halofuginone hydrobromide (1) is recognized as an effective drug against several species of Eimeria (E.) in poultry. In this paper, we describe a convenient and low cost preparation method for the compound, as well as primary validation of its activity. Methods: First, 7-bromo-6-chloroquinazolin-4(3H)-one (2) was prepared from m-chlorotoluene by a conventional process, and then chloroacetone was creatively introduced in two steps. Finally, halofuginone hydrobromide (1) was obtained from 7-bromo-6-chloro-3-(3-cholroacetonyl) quinazolin-4(3H)-one (4) by a four-step reaction sequence including condensation, cyclization, deprotection and isomerization. The structures of the relative intermediates and target compound were characterized by melting point, IR, MS and 1H-NMR. Besides, the protective effect of compound 1-supplemented chicken diet at doses of 6, 3 and 1.5 mg per 1 kg were evaluated on chickens infected with E. tenella, by reduction in mortality, weight loss, fecal oocyst excretion and gut pathology, respectively. Results: Halofuginone hydrobromide (1) was prepared successfully by and improved and innovative method based on traditional research. Moreover, the synthesized halofuginone hydrobromide significantly exhibited an anti-coccidial property. Conclusions: The fruitful work described in this Communication has resulted in halofuginone hydrobromide, which has a good pharmaceutical development prospects, becoming more available for large-scale production.

FUSED-RING PYRIMIDIN-4(3H)-ONE DERIVATIVES, PROCESSES FOR THE PREPARATION AND USES THEREOF

AbstractNovel compounds of the following formula (I) and pharmacologically acceptable salt and esters thereof can modulate LXR function and as a result show excellent anti-arteriosclerotic and anti-inflammatory activity:wherein:A represents aryl or heteroaryl;R1, R2 and R3 are the same or different and each represents hydrogen, hydroxyl, nitro, cyano, amino, halogen, carboxy, carbamoyl, mercapto, alkyl, haloalkyl, alkylcarbonyloxy, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylamino, dialkylamino, alkylcarbonylamino, N-(alkylcarbonyl)-N-(alkyl)amino, alkoxycarbonylamino, N-(alkoxycarbonyl)-N-(alkyl)amino, alkylsulfonylamino, N-(alkylsulfonyl)-N-(alkyl)amino, haloalkylsulfonylamino, N-(haloalkylsulfonyl)-N-(alkyl)amino, alkylcarbonyl, alkoxycarbonyl, alkylaminocarbonyl or dialkylaminocarbonyl group, or R1 and R2 together are alkylenedioxy;R4 and R5 are the same or different and each represents hydrogen, hydroxyl, amino, halogen, mercapto, alkyl, haloalkyl, alkoxy, alkoxycarbonyl or alkylthio;X represents hydrogen, hydroxyl, halogen, alkoxy or haloalkoxy; andY represents an optionally substituted alkyl, cycloalkyl, heterocyclyl, aryl, cycloalkylalkyl, heterocyclylalkyl or aralkyl group.

Process for the preparation of haloanthranilic acids

The present invention relates to a process for the preparation of compounds of the general formula I STR1 in which X and Y, independently of each other, represent hydrogen, fluorine, chlorine or bromine, but cannot simultaneously represent hydrogen, characterised in that compounds of the general formula II STR2 in which X and Y are defined as above, are reacted with aqueous ammonia under copper catalysis, and to intermediates for the preparation of compounds of the general formula I.